Both the companies collaborate on ProteoTech’s small molecule technology platform against misfolded proteins to work on its alpha-synuclein therapeutic program.
Michael J. Fox Foundation for Parkinson’s Research has provided funds for over a four-year period to support ProteoTech’s alpha-synuclein therapeutic research program.
ProteoTech CEO Steve Runnels said they are looking forward to work with GlaxoSmithKline on the identification and optimization of new therapeutic compounds for Parkinson’s and other synucleinopathies.